Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications
- PMID: 33910573
- PMCID: PMC8080398
- DOI: 10.1186/s12931-021-01729-5
Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications
Abstract
Background: Pseudomonas aeruginosa is one of the commonest bacteria colonizing the airway in patients with non-cystic fibrosis bronchiectasis. Pseudomonas aeruginosa colonization is associated with poor outcomes in patients with bronchiectasis, including rapid decline in lung function, exacerbation frequency and hospitalization.
Methods: A cross-sectional study in Queen Mary Hospital, Hong Kong that included 350 Chinese patients with non-cystic fibrosis bronchiectasis to investigate the risk factors for Pseudomonas aeruginosa colonization and clinical implications on disease outcomes.
Discussions: Pseudomonas aeruginosa colonization was more commonly found in patients with longer duration of bronchiectasis and those on proton pump inhibitors (PPIs) with adjusted ORs of 1.066 (95% CI = 1.036-1.096, p < 0.001) and 2.815 (95% CI = 1.307-6.064, p = 0.008) respectively. Patients with Pseudomonas aeruginosa colonization have more extensive lung involvement and higher risks of exacerbation requiring hospitalization with adjusted ORs of 2.445 (95% CI = 1.283-4.657, p = 0.007) and 2.745 (95% CI = 1.012-7.449, p = 0.047) respectively. Pseudomonas aeruginosa colonization is more common among patients with longer duration of bronchiectasis and those on PPI. Pseudomonas aeruginosa colonization is associated with more extensive lung involvement and higher risks of exacerbation requiring hospitalization.
Keywords: Bronchiectasis; Bronchiectasis exacerbation; Colonization; Non-cystic fibrosis bronchiectasis; Pseudomonas aeruginosa.
Conflict of interest statement
Nil.
Similar articles
-
Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance.Respir Med. 2015 Jun;109(6):716-26. doi: 10.1016/j.rmed.2014.07.021. Epub 2014 Aug 29. Respir Med. 2015. PMID: 25200914
-
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.Lancet Respir Med. 2019 Mar;7(3):213-226. doi: 10.1016/S2213-2600(18)30427-2. Epub 2019 Jan 15. Lancet Respir Med. 2019. PMID: 30658914 Clinical Trial.
-
Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study.BMJ Open. 2018 Mar 14;8(3):e014613. doi: 10.1136/bmjopen-2016-014613. BMJ Open. 2018. PMID: 29540404 Free PMC article.
-
How does Pseudomonas aeruginosa affect the progression of bronchiectasis?Clin Microbiol Infect. 2020 Mar;26(3):313-318. doi: 10.1016/j.cmi.2019.07.010. Epub 2019 Jul 12. Clin Microbiol Infect. 2020. PMID: 31306794 Review.
-
A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis.Ann Am Thorac Soc. 2015 Nov;12(11):1602-11. doi: 10.1513/AnnalsATS.201506-333OC. Ann Am Thorac Soc. 2015. PMID: 26356317 Review.
Cited by
-
Bacteriophage: A new therapeutic player to combat neutrophilic inflammation in chronic airway diseases.Front Med (Lausanne). 2022 Dec 14;9:1069929. doi: 10.3389/fmed.2022.1069929. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36590945 Free PMC article. Review.
-
Bacterial products initiation of alpha-synuclein pathology: an in vitro study.Sci Rep. 2024 Dec 5;14(1):30306. doi: 10.1038/s41598-024-81020-x. Sci Rep. 2024. PMID: 39639092 Free PMC article.
-
Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study.J Clin Med. 2023 Jun 9;12(12):3953. doi: 10.3390/jcm12123953. J Clin Med. 2023. PMID: 37373648 Free PMC article.
-
Epidemiology, Evolution of Antimicrobial Profile and Genomic Fingerprints of Pseudomonas aeruginosa before and during COVID-19: Transition from Resistance to Susceptibility.Life (Basel). 2022 Dec 7;12(12):2049. doi: 10.3390/life12122049. Life (Basel). 2022. PMID: 36556414 Free PMC article.
-
Clinical Impacts of Pseudomonas aeruginosa Isolation in Patients with Bronchiectasis: Findings from KMBARC Registry.J Clin Med. 2024 Aug 24;13(17):5011. doi: 10.3390/jcm13175011. J Clin Med. 2024. PMID: 39274224 Free PMC article.
References
-
- Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602–1611. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical